BEXSERO
Meningococcal group B (4CMenB) · Meningococcal (Men-C, ACYW, Men-B)
Health Canada DIN 02417030. Check the product and formulation on your record before using a schedule.
Plan doses for this product →At a glance
- Brand
- BEXSERO
- DIN
02417030- Vaccine
- Meningococcal group B (4CMenB)
- Presentation
- 0.5 mL · suspension · intramuscular · 2 months and older
- Live vaccine
- No
Age and suitability depend on the product, the person and the reason for vaccination. Use the planner for a starting point and confirm with the Care365 clinical team or doctor.
Official product information
Use the DIN to confirm this exact product in Health Canada's Drug Product Database.
Read product monograph (PDF) ↗
A listed product may not be stocked or publicly funded.
Dose schedules involving this product
These are Canadian Immunization Guide schedules associated with this DIN. The right schedule depends on age, health, prior doses and reason for vaccination.
| Schedule | Doses | Who it applies to |
|---|---|---|
| Meningococcal B (BEXSERO) — infants starting at 2 to 5 months Two doses 8 weeks apart plus a booster at 12 to 23 months of age. | 3 doses | For infants starting at 2 to 5 months of age when recommended (high-risk conditions, outbreak control or provincial programs): two (or three) primary doses at least 8 weeks apart, then a booster in the second year of life (12 to 23 months of age). |
| Meningococcal B (BEXSERO) — infants starting at 6 to 11 months Two doses at least 8 weeks apart plus a booster at 12 to 23 months of age. | 3 doses | For infants starting at 6 to 11 months of age: two doses at least 8 weeks apart, then a booster in the second year of life (12 to 23 months of age). |
| Meningococcal B (BEXSERO) — 12 months to 10 years, two doses Two doses at least 8 weeks apart. | 2 doses | For children 12 months to 10 years of age at increased risk (asplenia, complement deficiency, outbreak) or by individual decision: two doses at least 8 weeks apart. |
| Meningococcal B (BEXSERO) — 11 years and older, two doses Two doses at least 4 weeks apart. | 2 doses | For people 11 years of age and older at increased risk (asplenia, complement deficiency, laboratory exposure, outbreak) or by individual decision: two doses at least 4 weeks apart. |
Pregnancy and breastfeeding
Family guidance on pregnancy: Recommended when there is a high-risk condition, travel, an exposure or an outbreak.
Family guidance on breastfeeding: Recommended when there is a high-risk condition, travel, an exposure or an outbreak.
This guidance applies to the vaccine family. Confirm this product's details in the monograph and with your clinician. Immunization in pregnancy and breastfeeding: Canadian Immunization Guide — Chapter updated August 2026.
Sources and next steps
- Meningococcal vaccines: Canadian Immunization Guide — Chapter revised May 2015 · partial update March 2025
- Health Canada product record
General information only. A suggested date is not an appointment or a prescription; the Care365 clinical team or doctor confirms what you need. Clinical rules reviewed on 2026-09-27.
Review with Care365